Pharmacyclics, Inc. (NASDAQ:PCYC) said it entered an agreement with Roche to evaluate Imbruvica in combination with Gazyva for treatment of lymphoma and leukemia patients. Pharmacyclics, Inc. (NASDAQ:PCYC) said the master clinical drug supply agreement with Roche would study the safety, tolerability and preliminary efficacy of Imbruvica combined with Gazyva in patients with non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). The agreement allows for multiple studies to be conducted. Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.Cliffs Natural Resources Inc (NYSE:CLF) a mining and natural resources company, announced it expects to record a Q3 non-cash impairment of its long-lived assets of approximately $6 billion, after tax, for its seaborne iron ore and coal assets. The impairment is driven by the company's revised outlook for long-term pricing trends and adverse market conditions for seaborne iron ore and metallurgical coal in contrast to its more stable U.S. iron ore business.Cliffs Natural Resources Inc (NYSE:CLF) is working with its banking group for an amendment to eliminate the debt-to-capitalization covenant of 45% in its revolving credit facility, as the non-cash impairment charge will increase the ratio over the threshold. The company is confident that this amendment will be completed by the release of its Q3 earnings on October 27. Shares of CLF are trading within a 52-week range of $7.00 - $28.98.Entergy Corporation (NYSE:ETR) predicted its Q3 earnings below analysts' expectations Friday, but reiterated its 2014 earnings guidance. The energy company, primarily engaged in electric-power production and retail-distribution operations, said it expects Q3 2014 as-reported earnings of approximately $1.26 per share and operational earnings of approximately $1.67 per share, versus Q3 2013's as-reported earnings of $1.34 per share and operational earnings of $2.41 per share. Analysts polled by Capital IQ were recently projecting $2.08 per share for both earnings measures.Entergy Corporation (NYSE:ETR) said its utility posted another quarter-over-quarter of industrial sales growth, led by the Gulf region of the service territory, while it had a quarter-over-quarter decrease in operational earnings for Entergy Wholesale Commodities due to increased depreciation expense and a higher effective income tax rate on operational earnings. Entergy said it took steps to reduce uncertainty through a rate case settlement in Mississippi. Also, EWC received added clarity on the decommissioning of the Vermont Yankee Nuclear Power Station. Along with the rate case settlement, that resulted in charges in Q3 2014, the company said. For 2014, the company confirmed its prior guidance for operational earnings of $5.55 to $6.75 per share. Analysts recently were expecting $6.15. The company plans to release its full Q3 results before the market open on Nov. 4.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
